Citi Pharma Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0126201018
PKR
85.11
-1.37 (-1.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Jun'24
Jun'23
Jun'22
Jun'21
Jun'20
Jun'19
Net Sales
12,409.24
12,396.98
9,779.88
5,795.40
3,527.62
2,607.03
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
12,409.24
12,396.98
9,779.88
5,795.40
3,527.62
2,607.03
Raw Material Cost
11,009.70
10,955.79
8,484.16
5,052.55
3,112.81
2,291.44
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
553.42
453.83
340.48
248.65
169.26
145.10
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
299.91
140.55
64.19
40.78
43.92
18.46
Selling and Distribution Expenses
260.55
320.71
356.47
198.64
171.80
185.30
Other Expenses
-83.83
-58.47
-39.37
-28.94
-21.32
-16.36
Total Expenditure (Excl Depreciation)
11,285.27
11,286.17
8,851.60
5,251.18
3,284.61
2,476.74
Operating Profit (PBDIT) excl Other Income
1124
1110.8
928.3
544.2
243
130.29999999999998
Other Income
442.35
23.58
221.63
4.82
7.47
4.77
Operating Profit (PBDIT)
1,675.61
1,206.12
1,206.08
606.21
298.74
178.81
Interest
299.91
140.55
64.19
40.78
43.92
18.46
Exceptional Items
40.42
-19.26
-4.48
0.00
0.00
0.00
Gross Profit (PBDT)
1,399.53
1,441.19
1,295.72
742.86
414.81
315.59
Depreciation
138.22
90.59
76.83
65.69
52.29
46.08
Profit Before Tax
1,277.91
955.72
1,060.58
499.75
202.53
114.26
Tax
444.44
297.74
406.88
147.98
59.11
86.46
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
833.46
657.98
653.69
351.77
143.42
27.80
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
833.46
657.98
653.69
351.77
143.42
27.80
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
833.46
657.98
653.69
351.77
143.42
27.80
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
10.0
10.0
10.0
10.0
100.0
100.0
Reserves
5,633.13
5,373.07
4,713.98
4,366.05
978.31
837.75
Earnings per share (EPS)
3.65
2.88
2.88
2.15
28.97
5.62
Diluted Earnings per share
3.65
2.88
2.88
2.15
28.97
5.62
Operating Profit Margin (Excl OI)
8.82%
8.81%
9.28%
9.24%
6.77%
4.91%
Gross Profit Margin
11.41%
8.44%
11.63%
9.76%
7.22%
6.15%
PAT Margin
6.72%
5.31%
6.68%
6.07%
4.07%
1.07%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Jun 2024 is 0.10% vs 26.76% in Jun 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Jun 2024 is 26.67% vs 0.66% in Jun 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Jun 2024 is 4.30% vs 20.11% in Jun 2023

stock-summary

Interest

YoY Growth in year ended Jun 2024 is 113.45% vs 118.85% in Jun 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Jun 2024 has improved from Jun 2023

Compare Annual Results Of Citi Pharma Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(PKR)
Change(%)
Net Sales
12,409.24
15,854.75
-3,445.51
-21.73%
Other Operating Income
0.00
0.00
0.00
Total Operating income
12,409.24
15,854.75
-3,445.51
-21.73%
Raw Material Cost
11,009.70
9,651.39
1,358.31
14.07%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
553.42
2,711.24
-2,157.82
-79.59%
Power Cost
0
0
0.00
Manufacturing Expenses
299.91
670.61
-370.70
-55.28%
Selling and Distribution Expenses
260.55
4,574.79
-4,314.24
-94.30%
Other Expenses
-83.83
-338.18
254.35
75.21%
Total Expenditure (Excl Depreciation)
11,285.27
14,226.18
-2,940.91
-20.67%
Operating Profit (PBDIT) excl Other Income
1,123.97
1,628.57
-504.60
-30.98%
Other Income
442.35
157.33
285.02
181.16%
Operating Profit (PBDIT)
1,675.61
2,265.35
-589.74
-26.03%
Interest
299.91
670.61
-370.70
-55.28%
Exceptional Items
40.42
49.72
-9.30
-18.70%
Gross Profit (PBDT)
1,399.53
6,203.36
-4,803.83
-77.44%
Depreciation
138.22
538.11
-399.89
-74.31%
Profit Before Tax
1,277.91
1,106.36
171.55
15.51%
Tax
444.44
350.89
93.55
26.66%
Provisions and contingencies
0
0
0.00
Profit After Tax
833.46
683.15
150.31
22.00%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
833.46
683.15
150.31
22.00%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
72.33
-72.33
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
833.46
755.48
77.98
10.32%
Equity Capital
0
0
0.00
Face Value
10.00
10.00
0.00
Reserves
5,633.13
11,228.31
-5,595.18
-49.83%
Earnings per share (EPS)
3.65
15.72
-12.07
-76.78%
Diluted Earnings per share
3.65
15.72
-12.07
-76.78%
Operating Profit Margin (Excl OI)
8.82%
9.90%
0.00
-1.08%
Gross Profit Margin
11.41%
10.37%
0.00
1.04%
PAT Margin
6.72%
4.31%
0.00
2.41%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 1,240.92 Million
in Jun 2024

Figures in Million
stock-summary

YoY Growth in year ended Jun 2024 is 0.10% vs 26.76% in Jun 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 83.35 Million
in Jun 2024

Figures in Million
stock-summary

YoY Growth in year ended Jun 2024 is 26.67% vs 0.66% in Jun 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 123.33 Million
in Jun 2024

Figures in Million
stock-summary

YoY Growth in year ended Jun 2024 is 4.30% vs 20.11% in Jun 2023

Annual - Interest
Interest 29.99 Million
in Jun 2024

Figures in Million
stock-summary

YoY Growth in year ended Jun 2024 is 113.45% vs 118.85% in Jun 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 8.82%
in Jun 2024

Figures in %
stock-summary

YoY Growth in year ended Jun 2024 has improved from Jun 2023